{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:25:45Z","timestamp":1786116345659,"version":"build-2736575974"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03300-9","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:29:14Z","timestamp":1779085754000},"page":"1654-1658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Extended anticoagulation with DOACs in patients affected by hematologic malignancies and venous thromboembolism: a monocentric experience"],"prefix":"10.1007","volume":"59","author":[{"given":"M.","family":"Biglietto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. V.","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kasmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Chistolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"4","key":"3300_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1055\/s-0040-1708481","volume":"120","author":"A Abdulla","year":"2020","unstructured":"Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne SB, Lee AYY (2020) A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 120(4):702\u2013713","journal-title":"Thromb Haemost"},{"issue":"17","key":"3300_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM et al (2020) Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 382(17):1599\u20131607","journal-title":"N Engl J Med"},{"issue":"20","key":"3300_CR3","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023","journal-title":"J Clin Oncol"},{"issue":"7","key":"3300_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D et al (2018) Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624","journal-title":"N Engl J Med"},{"issue":"5","key":"3300_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 38(5):496\u2013520","journal-title":"J Clin Oncol"},{"issue":"347","key":"3300_CR6","doi-asserted-by":"publisher","first-page":"f5133","DOI":"10.1136\/bmj.f5133","volume":"30","author":"LA Castellucci","year":"2013","unstructured":"Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS et al (2013) Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network metaanalysis. BMJ 30(347):f5133","journal-title":"BMJ"},{"issue":"14","key":"3300_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","volume":"392","author":"I Mah\u00e9","year":"2025","unstructured":"Mah\u00e9 I, Carrier M, Mayeur D et al (2025) Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. N Engl J Med 392(14):1363\u20131373","journal-title":"N Engl J Med"},{"issue":"12","key":"3300_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.7326\/0003-4819-137-12-200212170-00008","volume":"137","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, Frulla M, Mosena L, Tormene D, Piccioli A, Simioni P, Girolami A (2002) Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 137(12):955\u2013960","journal-title":"Ann Intern Med"},{"issue":"17","key":"3300_CR9","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.3390\/jcm14175991","volume":"14","author":"M Bardetta","year":"2025","unstructured":"Bardetta M, Simoncini M, Valeri F, Pizzuto A, Dainese C, Sella C, Porreca A, Bruno B, Borchiellini A (2025) Residual Vein Thrombosis After Deep Vein Thrombosis in Patients Treated with DOACs: Incidence and Associated Factors. J Clin Med 14(17):5991","journal-title":"J Clin Med"},{"key":"3300_CR10","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. J Thromb Haemost 13:2119\u20132126","journal-title":"J Thromb Haemost"},{"key":"3300_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cncr.25714","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH (2011) Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 117:1334\u20131349","journal-title":"Cancer"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03300-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03300-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:16:55Z","timestamp":1786007815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03300-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":11,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["3300"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03300-9","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethic approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}